1365267-27-1

X-376 is an ALK inhibitor with potential efficacy in the treatment of non-small cell lung cancer.

The more common side effects of X-376 treatment include rash, itching, edema, and anemia.

Ensatinib (X-376) is a second-generation tyrosine kinase inhibitor (TKI) small-molecule targeted drug targeting ALK fusion, which can selectively bind to the products of two driver gene mutations, ALK and MET. Block the activation and transmission of downstream signaling pathways, thereby inhibiting the growth and proliferation of cancer cells with these mutations, and exerting anti-cancer effects.